QuantuMDx Group Ltd (QuantuMDx) operates as a developer of science tools and diagnostics products. The company’s products include Q-POC, a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious diseases and companion diagnostics assays and tumour profiling. QuantuMDx also develops technologies such as Q-PREP, Q-AMP, Q-DETECT, and Q-SEQ. The company’s devices are built using a range of complex technologies such as nanowires, microfluidic technologies, and molecular biology techniques. It serves clinics, pharmacies, hospitals and labs. The company has operations in the US and Singapore. QuantuMDx is headquartered in Newcastle Upon Tyne, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company QuantuMDx Group Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
QuantuMDx Group Ltd Company Overview
QuantuMDx Group Ltd Company Snapshot
QuantuMDx Group Ltd Pipeline Products and Ongoing Clinical Trials Overview
QuantuMDx Group Ltd – Pipeline Analysis Overview
QuantuMDx Group Ltd - Key Facts
QuantuMDx Group Ltd - Major Products and Services
QuantuMDx Group Ltd Pipeline Products by Development Stage
Sep 06, 2022: QuantuMDx and Sansure partner to commercialise Q-POC platform in China
May 26, 2021: QuantuMDx appoints Mirre de Noo as Non-Executive Director
Feb 13, 2021: Prime Minister, Boris Johnson visits QuantuMDx
Jan 21, 2021: QuantuMDx appoints Chief Commercial Officer
Jan 27, 2020: QuantuMDx: Leadership changes and business update
Nov 07, 2019: Find Initiates Feasibility Studies For Rapid, Low-Cost Diagnostics To Distinguish Gonorrhoea From Chlamydia In Primary Care Clinics
Apr 17, 2019: QuantuMDx Group has announced plans to expand the potential of its Q-POC technology and develop a quality control analytics system for cell and gene therapies (“C”s), to be evaluated by GlaxoSmithKline’s C platform group.
Apr 17, 2019: QuantuMDx develops QC analytics system for cell & gene therapies
Jan 23, 2019: QuantuMDx & St George’s begin field study: cervical cancer screening test